Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CX-2029 |
Synonyms | |
Therapy Description |
CX-2029 is a probody-drug conjugate that consists of CD71-targeted monoclonal antibody linked to a antigen-binding site masking peptide that is conjugated to the anti-microtubule agent monomethyl auristatin E (MMAE), which potentially induces cell cycle arrest and apoptosis of CD71-expressing tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CX-2029 | PDC-targeting CD71 CX-2029|CX 2029 | CX-2029 is a probody-drug conjugate that consists of CD71-targeted monoclonal antibody linked to a antigen-binding site masking peptide that is conjugated to the anti-microtubule agent monomethyl auristatin E (MMAE), which potentially induces cell cycle arrest and apoptosis of CD71-expressing tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03543813 | Phase Ib/II | CX-2029 | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL | Completed | USA | GBR | ESP | 1 |